News
Important Only
Portillo's Q4 revenue misses estimates
OverviewRestaurant chain's Q4 revenue rose 0.6% yr/yr but missed analyst expectationsNet income for Q4 decreased 49.5% yr/yr due to expense factorsCompany implemented strategic changes to improve business performanceOutlookPortillo's plans to open 8 new units in fiscal 2026Company expects mi...Reuters
19 minutes ago
Establishment Labs Q4 revenue beats on strong demand
OverviewMedical technology firm's Q4 revenue rose 45%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsNet income for Q4 exceeded analyst estimatesOutlookEstablishment Labs projects 2026 revenue between $264 mln and $266 mlnCompany expects 2027 revenue growth to be at le...Reuters
20 minutes ago
Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027
COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.Reuters
20 minutes ago
Iran issues death sentence linked to January unrest, source says
DUBAI, Feb 24 (Reuters) - A revolutionary court in Tehran has issued a death sentence for an Iranian man accused of "enmity against god", which if confirmed would be the first such sentence linked to mass protests in January, a source close to the man's family said.The source told Reuter...Reuters
21 minutes ago
Wyndham Hotels & Resorts Announces Launch Of Senior Notes Offering
Feb 24 (Reuters) - Wyndham Hotels & Resorts Inc WH.N:WYNDHAM HOTELS & RESORTS ANNOUNCES LAUNCH OF SENIOR NOTES OFFERINGWYNDHAM HOTELS & RESORTS INC - TO OFFER $650 MILLION SENIOR NOTES DUE 2033WYNDHAM HOTELS & RESORTS INC - PROCEEDS TO REPAY TERM LOAN A AND REVOLVING CREDIT FACILITYReuters
21 minutes ago
Novo Nordisk Announces Reduction In US List Price For Wegovy, Ozempic, Rybelsus
Feb 24 (Reuters) - Novo Nordisk A/S NOVOb.CO:NOVO NORDISK ANNOUNCES SIGNIFICANT REDUCTION IN US LIST PRICE FOR WEGOVY®, OZEMPIC®, AND RYBELSUS® (SEMAGLUTIDE MEDICINES), BUILDING ON CONTINUED EFFORTS TO EXPAND ACCESSNEW, LOWER LIST PRICE OF $675 PER MONTH ACROSS WEGOVY(®), OZEMPIC(®), AND RYBELSUS(®)...Reuters
22 minutes ago
Thermon Group Says If Deal Is Terminated, Co To Pay Ceco Environmental Termination Fee Of $74.70 Mln
Feb 24 (Reuters) - Thermon Group Holdings Inc THR.N:THERMON GROUP HOLDINGS - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO TO PAY CECO ENVIRONMENTAL TERMINATION FEE OF $74.70 MILLIONTHERMON GROUP HOLDINGS - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CECO ENVIRONMENTAL TO PAY CO A TER...Reuters
24 minutes ago
RPT-BREAKINGVIEWS-An $8 bln pharma deal prices patent fears
By Robert Cyran NEW YORK, Feb 23 (Reuters Breakingviews) - Pharmaceutical giants want to buy novel drug developers. The question is how much they’re willing to pay. Gilead Sciences’ GILD.O $7.8 billion purchase of biotechnology startup Arcellx ACLX.O, announced Monday at a 79% premium, indicates ...Reuters
28 minutes ago
RPT-BREAKINGVIEWS-Corporate America will harry trade warriors
By Gabriel Rubin WASHINGTON, Feb 23 (Reuters Breakingviews) - Last April, corporate America was blindsided by President Donald Trump’s unprecedented tariff barrage. Now, the fight over trade policy has moved onto their natural terrain: the courtroom. A $175 billion brawl over whether to refund le...Reuters
28 minutes ago
Alveus Therapeutics Announced Second & Final Closing Of Oversubscribed Series A Financing
Feb 24 (Reuters) - ALVEUS THERAPEUTICS : ANNOUNCED SECOND & FINAL CLOSING OF OVERSUBSCRIBED SERIES A FINANCING, INCREASING TOTAL ROUND SIZE TO $197 MILLIONALVEUS THERAPEUTICS: SECOND CLOSING INCLUDES PARTICIPATION FROM JEITO CAPITAL, NOVO HOLDINGS, ADDITIONAL HEALTHCARE-FOCUSED FUNDSReuters
28 minutes ago
